Influenza A virus H1N1 vaccine - Pfizer

Drug Profile

Influenza A virus H1N1 vaccine - Pfizer

Alternative Names: A/H1N1 influenza virus vaccine - Pfizer; Celvapan A/H1N1 pandemic vaccine - Pfizer; Celvapan H1N1; Inactivated H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived) - Pfizer; Swine flu vaccine - Pfizer

Latest Information Update: 15 Jun 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baxter International
  • Developer Pfizer
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H1N1 subtype

Most Recent Events

  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 01 Dec 2014 Pfizer acquired Baxter International’s marketed vaccines portfolio
  • 02 Aug 2010 Baxter re-initiates a phase I/I trial for Influenza-A virus H1N1 subtype (prevention, in infants, children and adolescents) in Austria and Germany (NCT00976469)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top